Irène Juhan‐vague

Irène Juhan‐vague's AcademicInfluence.com Rankings

Irène Juhan‐vague

Medical

#2619

World Rank

#3050

Historical Rank

Cardiology

#243

World Rank

#249

Historical Rank

medical Degrees

Download Badge

Medical

Why Is Irène Juhan‐vague Influential?

(Suggest an Edit or Addition)

(See a Problem?)

Irène Juhan‐vague's Published Works

Number of citations in a given year to any of this author's works

Total number of citations to an author for the works they published in a given year. This highlights publication of the most important work(s) by the author

Published Works

Plasma fibrinogen level and the risk of major cardiovascular diseases and nonvascular mortality: an individual participant meta-analysis. (2005) (1195)
Production of Plasminogen Activator Inhibitor 1 by Human Adipose Tissue: Possible Link Between Visceral Fat Accumulation and Vascular Disease (1997) (669)
Measurement of plasminogen activator inhibitor 1 in biologic fluids with a murine monoclonal antibody-based enzyme-linked immunosorbent assay. (1988) (593)
Fibrinolytic factors and the risk of myocardial infarction or sudden death in patients with angina pectoris. ECAT Study Group. European Concerted Action on Thrombosis and Disabilities. (1996) (591)
Correlation between blood fibrinolytic activity, plasminogen activator inhibitor level, plasma insulin level, and relative body weight in normal and obese subjects. (1986) (463)
C-Reactive Protein, Interleukin-6, and Fibrinogen as Predictors of Coronary Heart Disease: The PRIME Study (2003) (409)
PAI-1, Obesity, Insulin Resistance and Risk of Cardiovascular Events (1997) (399)
Deficient t-PA Release and Elevated PA Inhibitor Levels in Patients with Spontaneous or Recurrent Deep Venous Thrombosis (1987) (376)
Involvement of the hemostatic system in the insulin resistance syndrome. A study of 1500 patients with angina pectoris. The ECAT Angina Pectoris Study Group. (1993) (365)
Plasminogen activator inhibitor 1, transforming growth factor-beta1, and BMI are closely associated in human adipose tissue during morbid obesity. (2000) (362)
PAI-1 and the Metabolic Syndrome: Links, Causes, and Consequences (2006) (358)
Plasminogen activator inhibitor‐1, inflammation, obesity, insulin resistance and vascular risk (2003) (358)
Increased Plasminogen Activator Inhibitor Activity in Non Insulin Dependent Diabetic Patients – Relationship with Plasma Insulin (1989) (333)
C3H/HeJ mice carrying a toll-like receptor 4 mutation are protected against the development of insulin resistance in white adipose tissue in response to a high-fat diet (2007) (332)
Insulin Stimulates the Synthesis of Plasminogen Activator Inhibitor 1 by the Human Hepatocellular Cell Line Hep G2 (1988) (326)
Increased plasma plasminogen activator inhibitor 1 levels. A possible link between insulin resistance and atherothrombosis (1991) (314)
Common susceptibility alleles are unlikely to contribute as strongly as the FV and ABO loci to VTE risk: results from a GWAS approach. (2009) (304)
Plasma levels of a specific inhibitor of tissue-type plasminogen activator (and urokinase) in normal and pathological conditions. (1984) (265)
The Effect of Metformin on the Metabolic Abnormalities Associated With Upper-Body Fat Distribution. BIGPRO Study Group (1996) (258)
Clearance of tissue plasminogen activator (TPA) and TPA/plasminogen activator inhibitor type 1 (PAI-1) complex: relationship to elevated TPA antigen in patients with high PAI-1 activity levels. (1997) (241)
Effect of cytochrome p450 polymorphisms on platelet reactivity after treatment with clopidogrel in acute coronary syndrome. (2008) (238)
Contributions of Depressive Mood and Circulating Inflammatory Markers to Coronary Heart Disease in Healthy European Men: The Prospective Epidemiological Study of Myocardial Infarction (PRIME) (2005) (237)
Relationships between plasma insulin triglyceride, body mass index, and plasminogen activator inhibitor 1. (1987) (234)
Plasma Plasminogen Activator Inhibitor‐1 in Angina Pectoris: Influence of Plasma Insulin and Acute‐phase Response (1989) (231)
Associations of Fibrinogen, Factor VII and PAI-1 with Baseline Findings among 10,500 Male Participants in a Prospective Study of Myocardial Infarction (1998) (228)
Endothelial Cell Markers and the Risk of Coronary Heart Disease: The Prospective Epidemiological Study of Myocardial Infarction (PRIME) Study (2004) (220)
ADP-induced platelet aggregation and platelet reactivity index VASP are good predictive markers for clinical outcomes in non-ST elevation acute coronary syndrome (2007) (218)
Circulating endothelial microparticles in malawian children with severe falciparum malaria complicated with coma. (2004) (215)
Plasminogen Activator Inhibitor 1 and Atherothrombosis (1993) (210)
Stromal Cells Are the Main Plasminogen Activator Inhibitor‐1‐Producing Cells in Human Fat: Evidence of Differences Between Visceral and Subcutaneous Deposits (2002) (205)
Plasminogen activator inhibitor-1, adipose tissue and insulin resistance (2007) (192)
Insight into the nature of the CRP-coronary event association using Mendelian randomization. (2006) (191)
Metabolic syndrome, haemostasis and thrombosis (2008) (183)
ABCA1 gene deletion protects against cerebral malaria: potential pathogenic role of microparticles in neuropathology. (2005) (183)
Plasma PAI-1 Levels Are More Strongly Related to Liver Steatosis Than to Adipose Tissue Accumulation (2003) (178)
Plasma Thrombin-Activatable Fibrinolysis Inhibitor Antigen Concentration and Genotype in Relation to Myocardial Infarction in the North and South of Europe (2002) (175)
Metformin Decreases the High Plasminogen Activator Inhibition Capacity, Plasma Insulin and Triglyceride Levels in Non-Diabetic Obese Subjects (1987) (175)
Low-grade inflammation may play a role in the etiology of the metabolic syndrome in patients with coronary heart disease: the HIFMECH study. (2004) (165)
Identification of polymorphisms in the promoter and the 3' region of the TAFI gene: evidence that plasma TAFI antigen levels are strongly genetically controlled. (2001) (162)
Hypofibrinolysis and increased PAI-1 are linked to atherothrombosis via insulin resistance and obesity. (2000) (155)
The shedding activity of ADAM17 is sequestered in lipid rafts. (2006) (155)
Measurement of human tissue-type plasminogen activator by a two-site immunoradiometric assay. (1983) (153)
Thrombogenic and fibrinolytic factors and cardiovascular risk in non-insulin-dependent diabetes mellitus. (1996) (150)
Ser968Thr Mutation within the A3 Domain of Von Willebrand Factor (VWF) in Two Related Patients Leads to a Defective Binding of VWF to Collagen (2001) (147)
Fat distribution and plasminogen activator inhibitor activity in nondiabetic obese women. (1989) (145)
Platelets Potentiate Brain Endothelial Alterations Induced by Plasmodium falciparum (2006) (145)
Metabolic determinants are much more important than genetic polymorphisms in determining the PAI-1 activity and antigen plasma concentrations: a family study with part of the Stanislas Cohort. (1998) (143)
Influence of PAI-1 on adipose tissue growth and metabolic parameters in a murine model of diet-induced obesity. (2000) (139)
Endothelial cell dysfunction in HIV infection. (1992) (137)
Fibrinolytic and inflammatory processes in pleural effusions. (1995) (127)
Plasma cystatin-C and development of coronary heart disease: The PRIME Study. (2006) (126)
Effect of weight change and metformin on fibrinolysis and the von Willebrand factor in obese nondiabetic subjects: the BIGPRO1 Study. Biguanides and the Prevention of the Risk of Obesity. (1998) (126)
Incidence of activated protein C resistance caused by the ARG 506 GLN mutation in factor V in 113 unrelated symptomatic protein C-deficient patients. The French Network on the behalf of INSERM. (1995) (124)
Platelet microparticles: a new player in malaria parasite cytoadherence to human brain endothelium (2009) (122)
PAI-1 produced ex vivo by human adipose tissue is relevant to PAI-1 blood level. (1999) (122)
Plasminogen Activator Inhibitor-1 Expression in Human Liver and Healthy or Atherosclerotic Vessel Walls (1994) (120)
Subcutaneous abdominal, but not femoral fat expression of plasminogen activator inhibitor-1 (PAI-1) is related to plasma PAI-1 levels and insulin resistance and decreases after weight loss (2001) (120)
Stimulating effect of oxidized low density lipoproteins on plasminogen activator inhibitor-1 synthesis by endothelial cells. (1991) (117)
Five frequent polymorphisms of the PAI-1 gene: lack of association between genotypes, PAI activity, and triglyceride levels in a healthy population. (1997) (116)
Effect of atorvastatin and fluvastatin on the expression of plasminogen activator inhibitor type-1 in cultured human endothelial cells. (2000) (115)
Glucocorticoids and insulin promote plasminogen activator inhibitor 1 production by human adipose tissue. (1999) (110)
Biological and clinical features of low‐molecular‐weight heparin‐induced thrombocytopenia (2003) (107)
Plasma TAFI Antigen Variations in Healthy Subjects (2000) (105)
Increase in Plasma Concentrationof Plasminogen Activator Inhibitor, Fibrinogen, von Willebrand Factor, Factor VIII: Cand in Erythrocyte Sedimentation Rate with Age (1986) (104)
Development of a Genotype 325–Specific proCPU/TAFI ELISA (2003) (101)
Nutritionally Induced Obesity Is Attenuated in Transgenic Mice Overexpressing Plasminogen Activator Inhibitor-1 (2003) (101)
Antiphospholipids in hemodialysis patients: relationship between lupus anticoagulant and thrombosis. (1995) (100)
Visceral fat as a main determinant of plasminogen activator inhibitor 1 level in women (1998) (100)
Genetic Polymorphisms and Coronary Artery Disease in the South of France (2000) (98)
Thrombin-Activatable Fibrinolysis Inhibitor Antigen Levels and Cardiovascular Risk Factors (2000) (98)
Exclusive expression of transmembrane TNF-alpha in mice reduces the inflammatory response in early lipid lesions of aortic sinus. (2004) (97)
TGF-β1 Released from Activated Platelets Can Induce TNF-Stimulated Human Brain Endothelium Apoptosis: A New Mechanism for Microvascular Lesion during Cerebral Malaria1 (2006) (91)
Intracellular maturation and transport of tumor necrosis factor alpha converting enzyme. (2003) (91)
Modulation of Adipose Tissue Development by Pharmacological Inhibition of PAI-1 (2006) (90)
The TNF alpha converting enzyme (TACE/ADAM17) is expressed in the atherosclerotic lesions of apolipoprotein E-deficient mice: possible contribution to elevated plasma levels of soluble TNF alpha receptors. (2006) (90)
Activated thrombin activatable fibrinolysis inhibitor levels are associated with the risk of cardiovascular death in patients with coronary artery disease: the AtheroGene study (2009) (87)
Complexes between tissue-type plasminogen activator and proteinase inhibitors in human plasma, identified with an immunoradiometric assay. (1983) (87)
Relationship between aspirin and clopidogrel responses in acute coronary syndrome and clinical predictors of non response. (2009) (85)
Biological and genetic factors influencing plasma factor VIII levels in a healthy family population: results from the Stanislas cohort (2005) (84)
Plasminogen activator inhibitor-1 synthesis in the human hepatoma cell line Hep G2. Metformin inhibits the stimulating effect of insulin. (1993) (81)
The insulin resistance syndrome: implications for thrombosis and cardiovascular disease (2002) (80)
TLR4/Asp299Gly, CD14/C-260T, plasma levels of the soluble receptor CD14 and the risk of coronary heart disease: The PRIME Study (2004) (79)
On the role of coagulation and fibrinolysis in atherosclerosis. (1992) (76)
Protein S deficiency and HIV infection. (1991) (76)
Prognostic value of plasma tissue factor and tissue factor pathway inhibitor for cardiovascular death in patients with coronary artery disease: the AtheroGene study (2007) (75)
Plasmodium falciparum rhoptry protein RSP2 triggers destruction of the erythroid lineage. (2005) (75)
Antibodies to Phosphatidylethanolamine as the only Antiphospholipid Antibodies Found in Patients with Unexplained Thromboses (2001) (74)
The Ser 460 to Pro substitution of the protein S alpha (PROS1) gene is a frequent mutation associated with free protein S (type IIa) deficiency. (1995) (74)
Association of Plasminogen Activator Inhibitor (PAI)-1 (SERPINE1) SNPs With Myocardial Infarction, Plasma PAI-1, and Metabolic Parameters: The HIFMECH Study (2007) (70)
On the role of plasminogen activator inhibitor‐1 in adipose tissue development and insulin resistance in mice (2005) (68)
Adipose Tissue and Atherothrombosis (2003) (68)
TAFI gene haplotypes, TAFI plasma levels and future risk of coronary heart disease: the PRIME Study (2005) (67)
Adipose Tissue Expression of Gelatinases in Mouse Models of Obesity (2001) (66)
Increased PA-Inhibitor Levels in the Postoperative Period – No Cause-Effect Relation with Increased Cortisol (1985) (66)
EPCR Ser219Gly: elevated sEPCR, prothrombin F1+2, risk for coronary heart disease, and increased sEPCR shedding in vitro. (2005) (66)
The plasminogen activator inhibitor‐1 −675 4G/5G genotype influences the risk of myocardial infarction associated with elevated plasma proinsulin and insulin concentrations in men from Europe: the HIFMECH Study (2003) (65)
Weak and non‐independent association between plasma TAFI antigen levels and the insulin resistance syndrome (2003) (65)
The A -844G polymorphism in the PAI-1 gene is associated with a higher risk of venous thrombosis in factor V Leiden carriers. (2000) (65)
Association between TAFI antigen and Ala147Thr polymorphism of the TAFI gene and the angina pectoris incidence (2003) (64)
Plasma fibrinogen explains much of the difference in risk of coronary heart disease between France and Northern Ireland. The PRIME study. (2003) (64)
Identification of SAP97 as an intracellular binding partner of TACE (2003) (63)
Contribution of PAI-1 in cardiovascular pathology. (2004) (62)
Contribution of novel biomarkers to incident stable angina and acute coronary syndrome: the PRIME Study. (2008) (61)
Fibrinolysis and risk of coronary artery disease (1996) (61)
Treatment with metformin of non‐diabetic men with hypertension, hypertriglyceridaemia and central fat distribution: the BIGPRO 1.2 trial (2000) (60)
Fibrinolysis and atherosclerosis. (1988) (60)
Lack of association between the 807 C/T polymorphism of glycoprotein Ia gene and post-treatment platelet reactivity after aspirin and clopidogrel in patients with acute coronary syndrome (2007) (59)
Regulation of Fibrinolysis in the Development of Atherothrombosis: Role of Adipose Tissue (1999) (58)
Pathophysiology of fibrinolysis (1994) (57)
Collaborative meta-analysis of prospective studies of plasma fibrinogen and cardiovascular disease (2004) (57)
Hypofibrinolysis in the insulin resistance syndrome: implication in cardiovascular diseases (2004) (56)
Correlations between t-PA and PAI-1 antigen and activity and t-PA/PAI-1 complexes in plasma of control subjects and of patients with increased t-PA or PAI-1 levels. (1990) (56)
Potentiation by Heparin Fragments of Thrombolysis Induced with Human Tissue-Type Plasminogen Activator or Human Single-Chain Urokinase-Type Plasminogen Activator (1987) (56)
Adipocytokines and the risk of coronary heart disease in healthy middle aged men: the PRIME Study (2010) (55)
Systematically missing confounders in individual participant data meta-analysis of observational cohort studies (2009) (54)
Effect of Interleukin-6 promoter polymorphisms in survivors of myocardial infarction and matched controls in the North and South of Europe (2004) (52)
The Medi-RIVAGE study (Mediterranean Diet, Cardiovascular Risks and Gene Polymorphisms): rationale, recruitment, design, dietary intervention and baseline characteristics of participants (2004) (51)
Polymorphisms of the tumor necrosis factor-alpha (TNF) and the TNF-alpha converting enzyme (TACE/ADAM17) genes in relation to cardiovascular mortality: the AtheroGene study (2008) (51)
Effect of diet-induced weight loss on endothelial dysfunction: early improvement after the first week of dieting (2010) (50)
Relationships between alcoholic beverages and cardiovascular risk factor levels in middle-aged men, the PRIME Study. Prospective Epidemiological Study of Myocardial Infarction Study. (2001) (48)
Fat cell function and fibrinolysis. (2000) (48)
FHL2 interacts with both ADAM‐17 and the cytoskeleton and regulates ADAM‐17 localization and activity (2006) (48)
In Vivo Insulin Effect on ATPase Activities in Erythrocyte Membrane From Insulin-Dependent Diabetics (1987) (48)
Comparison of skin microvascular reactivity with hemostatic markers of endothelial dysfunction and damage in type 2 diabetes (2008) (47)
Clinical Features in 36 Patients Homozygous for the ARG 506 → GLN Factor V Mutation (1997) (46)
Plasma Determination of Plasminogen Activator Inhibitor 1 Antigen Must Be Performed in Blood Collected on Antiplatelet/Anticoagulant Mixture (1987) (46)
Fine mapping of quantitative trait nucleotides underlying thrombin-activatable fibrinolysis inhibitor antigen levels by a transethnic study. (2006) (45)
Quantification of thrombin activatable fibrinolysis inhibitor (TAFI) gene polymorphism effects on plasma levels of TAFI measured with assays insensitive to isoform-dependent artefact (2005) (44)
Measures to assess the prognostic ability of the stratified Cox proportional hazards model (2009) (44)
Accumulation of Triglyceride-Rich Lipoprotein in Subjects With Abdominal Obesity: The Biguanides and the Prevention of the Risk of Obesity (BIGPRO) 1 Study (2001) (44)
Formation, Inhibition and Clearance of Plasmin in vivo (2000) (43)
Relationships between Fibrinolytic and Inflammatory Parameters in Human Adipose Tissue: Strong Contribution of TNFα Receptors to PAI-1 Levels (2002) (43)
Upregulation of TNF‐α‐induced ICAM‐1 surface expression by adenylate cyclase‐dependent pathway in human endothelial cells (2005) (42)
Daytime Fluctuations of Plasminogen Activator Inhibitor 1 (PAI-1) in Populations with High PAI-1 Levels (1992) (42)
Effect of Atorvastatin on Adhesive Phenotype of Human Endothelial Cells Activated By Tumor Necrosis Factor Alpha (2003) (42)
Plasma Levels of Free and Total TFPI, Relationship with Cardiovascular Risk Factors and Endothelial Cell Markers (2001) (40)
Combined segregation-linkage analysis of plasma thrombin activatable fibrinolysis inhibitor (TAFI) antigen levels with TAFI gene polymorphisms (2001) (40)
Very high TAFI antigen levels are associated with a lower risk of hard coronary events: the PRIME Study (2003) (40)
Platelet function and composition in heart transplant recipients compared with nontransplanted coronary patients. (1992) (39)
Secretion of tissue-type plasminogen activator and plasminogen activator inhibitor by Rickettsia conorii- and Rickettsia rickettsii-infected cultured endothelial cells (1990) (39)
Hypofibrinolysis and insulin-resistance. (1991) (38)
Five novel mutations located in exons III and IX of the protein C gene in patients presenting with defective protein C anticoagulant activity. (1993) (37)
Interrelations between carbohydrates, lipids, and the hemostatic system in relation to the risk of thrombotic and cardiovascular disease. (1990) (36)
Fibrinolytic function and coronary risk (1999) (36)
A novel missense mutation shows that GPIbbeta has a dual role in controlling the processing and stability of the platelet GPIb-IX adhesion receptor. (2003) (34)
The arginine-552-cysteine (R1315C) mutation within the A1 loop of von Willebrand factor induces an abnormal folding with a loss of function resulting in type 2A-like phenotype of von Willebrand disease: study of 10 patients and mutated recombinant von Willebrand factor. (2001) (34)
ABO Blood Group and Risk of Venous Thrombosis in Heterozygous Carriers of Factor V Leiden (2000) (34)
Haemostatic parameters and vascular risk (1996) (33)
Phosphatidylinositol turnover during stimulation of plasminogen activator inhibitor-1 secretion induced by oxidized low density lipoproteins in human endothelial cells. (1993) (33)
Influence of t-PA and u-PA on Adipose Tissue Development in a Murine Model of Diet-Induced Obesity (2002) (33)
Upregulation of TNF-alpha-induced ICAM-1 surface expression by adenylate cyclase-dependent pathway in human endothelial cells. (2005) (31)
The increased plasma Lp(a): B lipoprotein particle concentration in angina pectoris is not associated with hypofibrinolysis. (1990) (31)
Activation of coagulation in decompression illness. (1998) (30)
p38 mitogen activated protein kinase controls two successive-steps during the early mesodermal commitment of embryonic stem cells. (2011) (29)
Effect of 24 Hours of Normoglycaemia on Tissue-Type Plasminogen Activator Plasma Levels in Insulin Dependent Diabetes (1984) (29)
Detection of Plasminogen Activator Inhibitor-1 (PAI-1) mRNA in Human Megakaryocytes by In Situ Hybridization (1994) (29)
Association of vitronectin and plasminogen activator inhibitor-1 levels with the risk of metabolic syndrome and type 2 diabetes mellitus (2011) (29)
Up-regulation of PAI-1 Synthesis by Insulin and Proinsulin in HEP G2 Cells but not in Endothelial Cells (1995) (28)
Association of a sequence variant in DAB2IP with coronary heart disease (2011) (27)
Fluvastatin Decreases Soluble Thrombomodulin in Cardiac Transplant Recipients (2000) (27)
Protein Z plasma levels are not associated with the risk of coronary heart disease: the PRIME Study (2004) (27)
[Prevention of deep venous thrombosis of the leg by a very low molecular weight heparin fraction (CY 222) in patients with hemiplegia following cerebral infarction: a randomized pilot study (30 patients)]. (1990) (27)
Assessment of D-dimer measurement by ELISA or latex methods in deep vein thrombosis diagnosed by ultrasonic duplex scanning (1990) (27)
Intracellular calcium mobilization suppresses the TNF-alpha-stimulated synthesis of PAI-1 in human endothelial cells. Indications that calcium acts at a translational level. (1997) (27)
Plasminogen Activator Inhibitor Activity in Various Types of Endogenous Hypertriglyceridemia (1993) (26)
Released from Activated Platelets Can Induce TNF-Stimulated Human Brain Endothelium Apoptosis: A New Mechanism for Microvascular Lesion during Cerebral Malaria (2005) (26)
Tiplaxtinin impairs nutritionally induced obesity in mice (2006) (26)
Fibrinogen, fibrinolysis and diabetes mellitus: a comment (1997) (26)
Association of hypertensive status and its drug treatment with lipid and haemostatic factors in middle-aged men: the PRIME Study (2000) (24)
Interaction between the C-260T polymorphism of the CD14 gene and the plasma IL-6 concentration on the risk of myocardial infarction: the HIFMECH study. (2005) (24)
Characterization of Epitheloid Cells from Human Omentum: Comparison with Endothelial Cells from Umbilical Veins (1991) (24)
Iloprost and salvage of a free flap. (1996) (24)
Up-Regulated Expression of Plasminogen Activator Inhibitor-1 in Hep G2 Cells: Interrelationship between Insulin and Insulin-Like Growth Factor 1 (1995) (22)
Hemobiology, vascular disease, and diabetes with special reference to impaired fibrinolysis. (1992) (22)
Activation of Plasminogen Activator Inhibitor-1 Synthesis by Phorbol Esters in Human Promyelocyte HL-60 (1999) (22)
Molecular forms of plasminogen activator inhibitor-1 (PAI-1) and tissue-type plasminogen activator (t-PA) in human plasma. (1991) (22)
Fibrinolysis in insulin dependent diabetic patients with or without nephropathy (1992) (21)
New Direct Assay of Free Protein S Antigen Applied to Diagnosis of Protein S Deficiency (1996) (21)
Bivariate familial correlation analysis of quantitative traits by use of estimating equations: Application to a familial analysis of the insulin resistance syndrome (1999) (21)
Prothrombin G20210A carriers the genetic mutation and a history of venous thrombosis contributes to thrombin generation independently of factor II plasma levels (2010) (20)
Effect of Atorvastatin on Plasminogen Activator Inhibitor Type‐1 Synthesis in Human Monocytes/Macrophages (2001) (20)
Proteasome inhibition activates the transport and the ectodomain shedding of TNF-α receptors in human endothelial cells (2005) (20)
In vivo stimulation of neutrophil function by lenograstim (glycosylated rHug‐CSF) in oncohematologic patients: Results of a phase I trial (1994) (20)
Thr325IIe polymorphism of the TAFI gene does not influence the risk of myocardial infarction. (2002) (19)
Effects of DDAVP and venous occlusion on the release of tissue-type plasminogen activator and von Willebrand factor in patients with panhypopituitarism. (1984) (19)
4 Pathophysiology of fibrinolysis (1995) (19)
Effect of low density lipoproteins on secretion of plasminogen activator inhibitor-1 (PAI-1) by human endothelial cells and hepatoma cells. (1990) (19)
Fibrinogen, obesity and insulin resistance. (1999) (19)
Relation between Plasma PAI Activity and Adipsin Levels (1995) (18)
Plasma reactivity to hexagonal II phase phosphatidylethanolamine is more frequently associated with lupus anticoagulant than with antiphosphatidylethanolamine antibodies. (1993) (18)
[Cerebral phlebitis and Crohn disease]. (1992) (18)
A new mutation, S1285F, within the A1 loop of von Willebrand factor induces a conformational change in A1 loop with abnormal binding to platelet GPIb and botrocetin causing type 2M von Willebrand disease (2003) (18)
Rapid Detection of Factor XIII Val34Leu by Allele Specific PCR (1999) (18)
Functional consequences of the Ser334-->Pro mutation in a human factor X variant (factor XMarseille). (1995) (18)
Increase in cytosolic calcium upregulates the synthesis of type 1 plasminogen activator inhibitor in the human histiocytic cell line U937. (1996) (17)
[From fibrinogen to fibrin and its dissolution]. (2003) (17)
Ala147Thr and C+1542G Polymorphisms in the TAFI Gene Are not Asssociated with a Higher Risk of Venous Thrombosis in FV Leiden Carriers (2001) (17)
Plasma fibrinogen concentration predicts the risk of myocardial infarction differently in various parts of Europe: effects of β-fibrinogen genotype and environmental factors (2004) (17)
Measurement of Low Molecular Weight Heparin Ex Vivo Activities in Clinical Laboratories Using Various Anti-Xa Assays: Interlaboratory Variability and Requirement for an Agreed Low Molecular Weight Heparin Standard (1987) (17)
Micronized fenofibrate normalizes the enhanced lipidemic response to a fat load in patients with type 2 diabetes and optimal glucose control. (2003) (17)
Resistance to Activated Protein C – Diagnostic Strategy in a Laboratory of Haemostasis (1995) (17)
Plasminogen activator inhibitor 1 and insulin levels in various insulin resistance states. (1992) (17)
A Three-generation Family Presenting Five Cases of Homozygosity for the 20210 G to A Prothrombin Variant (1998) (17)
Unfading acral microlivedo. A discrete marker of thrombotic skin disease associated with antiphospholipid antibody syndrome. (1991) (17)
Increase in cytosolic calcium upregulates the synthesis of type 1 plasminogen activator inhibitor in the human histiocytic cell line U937 (1996) (15)
Tumor Necrosis Factor α Up-regulates in an Autocrine Manner the Synthesis of Plasminogen Activator Inhibitor Type-1 during Induction of Monocytic Differentiation of Human HL-60 Leukemia Cells* (2000) (15)
Leukocyte Activation Study During Occlusive Arterial Disease of the Lower Limb: Effect of Pentoxifylline Infusion (1995) (15)
Inhibition of p70S6 Kinase during Transforming Growth Factor-β1/Vitamin D3-induced Monocyte Differentiation of HL-60 Cells Allows Tumor Necrosis Factor-α to Stimulate Plasminogen Activator Inhibitor-1 Synthesis* (2001) (14)
Specificity of an Assay Based on a Factor V-depleted Plasma in Patients Carrying the Arg 506 GIn Mutation (1996) (14)
Rapid modifications of biophysical and biochemical parameters of red blood cell membrane from insulin dependent diabetics after insulin administration. (1986) (14)
Chronic plasminogen activator inhibitor‐1 (PAI‐1) overexpression dampens CD25+ lymphocyte recruitment after lipopolysaccharide endotoxemia in mouse lung (2007) (13)
Fibrinolysis and atherothrombosis (1993) (13)
PLASMA HISTIDINE-RICH GLYCOPROTEIN AND THROMBOPHILIA (1988) (13)
Correction by insulin added in vitro of abnormal membrane fluidity of the erythrocytes from Type 1 (insulin-dependent) diabetic patients (1986) (12)
Acquired Protein S Deficiency, Likely due to Anti-PS Autoantibodies, following a Thrombotic Event in a Patient with a Systemic Lupus erythematosus (1997) (12)
Polymorphism A36G of the tumor necrosis factor receptor 1 gene is associated with PAI-1 levels in obese women (2006) (12)
Cutaneous Necrosis Associated with Acquired Severe Protein S Deficiency (1993) (11)
Modulation of PAI‐1 and proMMP‐9 syntheses by soluble TNFα and its receptors during differentiation of the human monocytic HL‐60 cell line (2003) (11)
Relevance of Free tPA Assay Following Venous Occlusion in Patients with Venous Thromboembolic Disease (1988) (11)
CLINICAL RELEVANCE OF HIGH PAI-1 LEVEL IN PATIENTS WITH IDIOPATHIC/RECURRENT DEEP VENOUS THROMBOSIS (1988) (10)
ABDOMINAL OBESITY, INSULIN RESISTANCE, AND ALTERATIONS IN HEMOSTASIS (2008) (10)
Comparison of the effects of aspirin and indomethacin on aortic atherogenesis induced in rabbits. (1982) (10)
Platelet antibodies in Mediterranean tick typhus. (1985) (10)
Interleukin-2 induces chemotactic deficiency in patients with onco hematologic malignancies and autologous bone marrow transplantation. (1991) (9)
Respective contribution of conventional risk factors and antihypertensive treatment to stable angina pectoris and acute coronary syndrome as the first presentation of coronary heart disease: the PRIME Study (2009) (9)
A 13 base pair deletion in the GPIbβ gene in a second unrelated Bernard–Soulier family due to slipped mispairing between direct repeats (2004) (9)
PAI-1, Obesity, and Insulin Resistance (1999) (9)
Haemostasis in relation to dietary fat as estimated by erythrocyte fatty acid composition: the prime study. (2001) (9)
[Klinefelter's syndrome and leg ulcers: role of blood coagulation disorders]. (1992) (9)
Screening for identified and unidentified protein C pathway defects by the Agkistrodon contortrix venom test in consecutive patients. (1999) (8)
CLINICAL RELEVANCE OF REDUCED t-PA RELEASE UPON VENOUS OCCLUSION IN PATIENTS WITH IDIOPATHIC / RECURRENT DEEP VENOUS THROMBOSIS (1988) (8)
The Fibrinolytic System and Obesity (2002) (8)
Molecular characterization of a novel mutation in the factor XIII a subunit gene associated with a severe defect: importance of prophylactic substitution. (2009) (8)
The determination of functional plasminogen activator inhibitors (PAI) based on the inhibition of urokinase: PAI normal range and circadian variations in healthy donors; Comparison with other methods (1990) (8)
MEASUREMENT OF PLASMINOGEN ACTIVATOR INHIBITOR 1 (PAI-1) IN PLASMA WITH AN ELISA BASED ON TWO MURINE MONOCLONAL ANTIBODIES (1987) (8)
Protein S deficiency: different biological phenotypes according to the assays used. (1998) (7)
Measurement of Blood Heparin Levels - variation in Results with Assay Method (1982) (7)
Purpura Fulminans in a Patient Homozygous for a Mutation in the Protein C Gene - Prenatal Diagnosis in a Subsequent Pregnancy (1996) (7)
Treatment of Venous Thrombosis and Pulmonary Embolism by Streptokinase (1978) (7)
Vascular Development and Vessel Remodelling Association between TAFI antigen and Ala 147 Thr polymorphism of the TAFI gene and the angina pectoris incidence The PRIME Study (2003) (6)
Binding of 99mTc Plasminogen on Fibrin (1981) (6)
Tumor necrosis factor alpha up-regulates in an autocrine manner the synthesis of plasminogen activator inhibitor type-1 during induction of monocytic differentiation of human HL-60 leukemia cells. (2000) (6)
Factor XIIIV34L is not an additional genetic risk factor for venous thrombosis in Factor V Leiden carriers (2001) (6)
Prospective analysis of factor XI deficiencies in the Marseilles area identified four novel mutations among 12 consecutive unrelated families (2009) (6)
Intraperitoneal Insulin Administration Does Not Modify Plasminogen Activator Inhibitor 1 Levels in IDDM Patients (1994) (6)
Venous Occlusion Does Not Induce the Release of Thrombomodulin from Endothelial Cells in Patients with Thromboembolic Disease (1992) (6)
The effect of plasma proteins and glycosylated fibrinogen on red blood cell aggregation in diabetes (1991) (6)
Proinflammatory properties of murine aortic endothelial cells exclusively expressing a non cleavable form of TNFα (2004) (6)
Treatment of deep vein thrombosis with a very low molecular weight heparin (CY 222 - Choay): Thrombolysis and plasma fibrinolytic parameters (1988) (5)
Catastrophic Arterial Reactivity During Primary Antiphospholipid Syndrome (1999) (5)
[Disseminated intravascular coagulation masking neonatal hemophilia]. (1991) (5)
Polymorphisms of the lamina maturation pathway and their association with the metabolic syndrome: the DESIR prospective study (2010) (5)
Natural inhibitors of fibrinolysis. (1986) (5)
PPARα deficiency does not modify age dependency but prevents high fat diet increase in plasma PAI-1 as well as insulin resistance (2004) (5)
[Heterozygous prothrombin gene mutation G20210A and associated diseases]. (2003) (5)
[Dyslipidemia, lipid lowering drugs and thrombosis]. (1995) (4)
Possible participation of adenosine 5'-diphosphate, arachidonic acid and paf-acether in the platelet pro-aggregating effect of uncontrolled insulin-dependent diabetic erythrocytes in vitro. (1985) (4)
Common variants in the thrombomodulin gene as a risk for myocardial infarction in the north of Europe (HIFMECH Study) (2004) (4)
[The significance of the levels of D-dimer in thrombotic conditions]. (1988) (4)
Pentoxifylline in vitro reverses neutrophil chemotactic deficiency induced by interleukin-2 treatment. (1992) (4)
Spontaneous adult scurvy in a developed country: new insight in an ancient disease. (1990) (4)
Fibrinolytic activity in experimental vascular grafts. (1983) (4)
Plasma Plasminogen Activator Inhibitor Activity in Rats with Nutritionally Induced Insulin Resistance (1995) (3)
[Endothelium, thrombosis and fibrinolysis]. (1997) (3)
Anti‐phospholipid/cofactor antibodies in three cases of persistent polyclonal b lymphocytosis (2002) (3)
Correction by pentoxifylline of the abnormal fluorescence polarization of erythrocyte membranes from diabetic patients (2004) (3)
Fibrinolytic anomalies associated with insulin resistance. Effect of metformin. Results of the Bigpro trial (1994) (3)
Insulin resistance and alterations in the fibrinolytic system (1993) (3)
[Thromboembolic disease and anomalies of fibrinolysis]. (1986) (2)
In vitro inhibition of interleukin‐2‐induced defective polymorphonuclear chemotaxis by TNF inhibitor (1993) (2)
79. Fibrinolytic factors and the risk of cardiovacular disease (1996) (2)
[Morphologic study of different types of venous grafts. Correlation trial with parietal fibrinolytic activity]. (1982) (2)
Relations between hemostatic variables, insulin resistance and inflammation. (2004) (2)
Variables of the fibrinolytic system: risk indicators for CHD (1997) (2)
PAI-1 and the Risk of Cardiovascular Disease (1998) (2)
CLINICAL RELEVANCE OF PLASMA FIBRIN DEGRADATION PRODUCTS DETERMINATION IN PATIENTS WITH DEEP VEIN THROMBOSIS (DVT) (1987) (2)
Pathophysiology of fibrinolysis. (1995) (2)
[Immunologic determination of the protein C of coagulation: detection of deficiencies]. (1985) (2)
[Septicemia, portal thrombosis and congenital protein C deficiency]. (1988) (2)
Potentiation by heparin fragment CY 222 (Choay) of thrombolysis induced by human tissue-type plasminogen activator. (1989) (2)
Tissue-type plasminogen activator antigen (t-PA Ag) (1992) (2)
[The link between molecules produced by the adipose tissue, obesity and atherothrombosis]. (2005) (2)
In vitro Effect of Pentoxifylline on Leukocyte Functions in Myocardial Infarction (1990) (1)
PARALLEL VARIATIONS OF PLASMA INSULIN, TRIGLYCERIDE AND PLASMINOGEN ACTIVATOR INHIBITOR 1 (PAI 1) LEVELS IN OBESE NON DIABETIC SUBJECTS (1987) (1)
EFFECT OF DIFFERENT HEPARINS ON THROMBOLYSIS WITH t-PA AND scu-PA IN RABBITS WITH EXPERIMENTAL THROMBOSIS (1987) (1)
Lupus anticoagulants and antiphospholipid antibodies: comparison of clotting tests with an immunological assay. (1990) (1)
Fibrinolytic a and iinflammatory p processes iin p pleural e effusions (1995) (1)
[The effect of pentoxifylline and propentofylline on the membrane fluidity of red blood cells in uncontrolled insulin-dependent (type 1) diabetic patients]. (1988) (1)
DO APTT AND ANTI Ila ACTIVITY PERMIT THE PREDICTION OF THE EFFICIENCY OF HEPARIN THERAPY IN PATIENTS WITH PROXIMAL DEEP VEIN THROMBOSIS? (1987) (1)
Acquired inhibitor of thrombin associated with an ulcerative colitis (2000) (1)
Hémophilie acquise par anticorps antifacteur VIIIc. A propos de 3 observations (1983) (1)
[Evaluation of a functional test in the screening of protein S deficiency]. (2003) (1)
Erythrocyte rheology in diabetes mellitus (2016) (1)
[Anti-activator inhibitors of plasminogen]. (1987) (1)
Hyperactive polymorphonuclear leucocytes migration in patients with familial Mediterranean fever (1996) (1)
[Erythrocyte and platelet parameters and degree of control of diabetes]. (1982) (1)
16 Plasma insulin could regulate plasma PAI-1 concentration (1988) (1)
A 36 G of the tumor necrosis factor receptor 1 gene is associated with PAI-1 levels in obese women (2018) (1)
Abstract 1026: Systemic Chemokines Levels and Incident Coronary Heart Disease and Ischemic Stroke Events in Asymptomatic Middle-aged Men: The Prime Study (2009) (1)
Humans clear active t-pa faster than t-pa/pai-1 complex (1996) (1)
In vivo cytokines effects on polymorphonuclear cells functions (1992) (1)
Effect of calcium-chelating and non-chelating anticoagulants on erythrocyte and leucocyte filterability (2016) (1)
Anticoagulants and erythrocyte filterability. (1984) (1)
Study of PAI-1 expression during endothelial cell cycle (1994) (0)
Clinical significance of apolipoprotein B containing lipoprotein particles (1990) (0)
Tu-W19:2 Role of the fibrinolytic system in the development of obesity and the metabolic syndrome (2006) (0)
Hemostatic abnormalities associated with obesity and the metabolic syndrome (2005) (0)
Abstract Poster presentations P-9: Regulation of fibrinolysisCytosolic phospholipase a2 activity in resting and tnf-stimulated cultured human endothelial cells (1994) (0)
Anticoagulant effects on the measurement of erythrocyte filterability (1985) (0)
Welcome Address by Prof. A. Serradimigni (1986) (0)
Erythrocyte deformability and acute phase reactant proteins in arteriosclerosis obliterans patients (2016) (0)
Treatment of deep vein thrombosis (DVT) with LMWH CY 222. Modifications of biological parameters (1986) (0)
Post-prandial lipemia in type II — Diabetic patients under optimised metabolic control — Effects of fenofibrate (1995) (0)
ID: 035 Role of the fibrinolytic system in the development of obesity and the metabolic syndrome (2006) (0)
Hypofibrinolysis and Hyperinsulinemia (2019) (0)
[Thromboembolic risk remains uncertain in protein C deficiency]. (1985) (0)
U937 plasminogen activator inhibitor in the human histiocytic cell line Increase in cytosolic calcium upregulates the synthesis of type 1 (2011) (0)
Abnormalities of erythrocyte membrane lipids in insulin-dependent diabetics are improved by short term strict control of diabetes (2016) (0)
Lipopolysaccharide-induced endotoxemia in the mouse is aggrevated by PAI-1 overexpression (2005) (0)
[Atheroma and antithrombotic agents]. (1992) (0)
Plasminogen activator inhibitor 1 (PAI-1) gene expression in human megacaryocytes (1994) (0)
Platelet microparticles: a new player in cerebral malaria pathogenesis (2008) (0)
Session 7: Regulation and modulation of fibrinolysis39 Insulin increases the synthesis of plasminogen activator inhibitor 1 by an hepatocellular cell line (HEP 62) (1988) (0)
activatable fibrinolysis inhibitor antigen levels by a trans-ethnic study Fine mapping of quantitative trait nucleotides underlying thrombin (2013) (0)
Platelet microparticles enhance Plasmodium falciparum‐parasitised red blood cell cytoadherence and activate human brain endothelial cells (2008) (0)
Plasma plasminogen activator-1 level (PAI-1 L) increase after thrombolytic therapy. A randomized-controlled study with streptokinase (SK) and recombinant tissue-type plasminogen activator (rt-PA) (1996) (0)
Hemostatic Abnormalities in Diabetes (2003) (0)
Federal autonomy and the politics of reform: the standardization of mortality statistics in Germany c.1850-1914. (2001) (0)
[Thrombolytics and their use]. (1999) (0)
International society for fibrinolysis and thrombolysis (ISFT) minutes of the General Assembly, Florence, 9 June 1997 (1997) (0)
[Ophthalmic vein thrombosis and G1691A mutation of factor V gene]. (1999) (0)
« Hémophilie acquisepar anticorps antifacteur VIII c: A propos de 3 observations (1983) (0)
Contents Vol. 32, 2002 (2002) (0)
2.W14.3 Impaired fibrinolysis and the risk of CHD (1997) (0)
We-W35:2 Inherited and acquired risk factors for juvenile myocardial infarction in an European cohort (2006) (0)
Contents Vol. 33 (2003) (0)
[Aneurysm of the abdominal aorta and preoperative disseminated intravascular coagulation]. (1991) (0)
Biological Variations in t-PA Activator Activity and Antigen (2018) (0)
Relationship between insulin and IGF-1 in the up-regulation of PAI-1 synthesis in hep G2 cells (1994) (0)
Monitoring of fibrinolytic treatment with chromogenic substrate assays. (1982) (0)
[Lipid indicators of vascular risk. A cross-sectional study of a group of coronary patients, a group of subjects with normal coronary angiography and a control group]. (1992) (0)
[Development in the bone marrow and liver following androgen therapy prolonged by Fanconi's anemia (proceedings)]. (1977) (0)
[Natural inhibitors of fibrinolysis]. (1986) (0)
Regulation of PAI-1 in obesity and insulin resistance (1999) (0)
Principles for the design of rheological studies in diabetes mellitus (2016) (0)
[Fibrinolytic system and hyperinsulinism]. (1990) (0)
Molecular-forms of plasminogen-activator inhibitor-1 (pai-1) in plasma (1989) (0)
PAI-l AND THE RISK OF CARDIOVASCULAR DISEASE (1998) (0)
Factor XIIIV34L is not an additional genetic risk for venous thrombosis in factor V Leiden carriers. (2001) (0)
[Acquired hemophilia caused by antifactor VIIIc antibodies. Apropos of 3 cases]. (1983) (0)
Haemorheological results in a large multicentre study of claudicants treated with ketanserin (2016) (0)
Subject Index, Vol. 16, Supplement 3, 1986 (1986) (0)
Contents, Vol. 16, Supplement 3, 1986 (1986) (0)
Title Page / Table of Contents / Preface (2003) (0)
The fibrinolytic system in dysmetabolic diseases (1993) (0)
Vitronectin levels predict metabolic syndrome and diabetes mellitus risks through a PAI-1 dependent mechanism: a 9 year follow-up from the D.E.S.I.R. prospective cohort (2010) (0)
RELEVANCE OF FREE t-PA ASSAY FOLLOWING VENOUS OCCLUSION IN PATIENTS WITH VENOUS THROMBOEMBOLIC DISEASE (1987) (0)
B013 Genetic polymorphisms of the lamina maturation pathway and their association with the metabolic syndrome: the desir prospective study (2009) (0)
DETERMINATION OF PA INHIBITOR 1 (PA INHIBITOR ACTIVITY AND PA INHIBITOR 1 ANTIGEN) IN PLASMA BEFORE AND AFTER VENOUS OCCLUSION (1987) (0)
Results Effect of PAI-039 on PAI-1 Secretion by Preadipocytes : Basal (2006) (0)
Plasminogen activator inhibitor 1 (PAI-1) and insulin-resistance (1990) (0)
14 HEMOPHILIA IN FEMALE PHENOTYPIC PATIENTS (1979) (0)
[abstract] USE OF NEW HEMOSTATIC MARKERS IN DECOMPRESSION ACCIDENTS IN DEEPSEA DIVING (Preliminary results) (1993) (0)
[Low molecular weight heparin CY 222 (Choay) potentiates the thrombolytic effect of 1-PA in rabbits with experimental thrombosis of the jugular vein]. (1987) (0)
Lupus anticoagulant in silica-induced scleroderma (1992) (0)
ID: 282 PAI-1 modulates the inflammatory response during Lipopolysaccharide (LPS)-induced endotoxemia. (2006) (0)
[Aging of the arterial wall: endothelium, thrombosis and fibrinolysis]. (1991) (0)
Blood Coagulation, Fibrinolysis and Cellular Haemostasis Association of vitronectin and plasminogen activator inhibitor-1 levels with the risk of metabolic syndrome and type 2 diabetes mellitus Results from the D.E.S.I.R. prospective cohort (2017) (0)
[Is hypofibrinolysis a risk factor of thrombosis?]. (1989) (0)
PAI-1 GENE HAPLOTYPES ARE ASSOCIATED WITH MYOCARDIAL INFARCTION OCCURRENCE IN NON SMOKERS: THE HIFMECH STUDY (2007) (0)
Overexpression of PAI-1 Does Not Affect Adipose Tissue Development in Mice on SFD (2002) (0)
Fibrinolysis and the metabolic syndrome (2007) (0)
[Detection of platelet antibodies in idiopathic thrombopenic purpura]. (1987) (0)
[Factor X deficiency and systemic amylosis]. (1984) (0)
insulin and acute-phase response Plasma plasminogen activator inhibitor-1 in angina pectoris. Influence of plasma (2011) (0)

This paper list is powered by the following services:

Irène Juhan‐vague's Academic­Influence.com Rankings

Why Is Irène Juhan‐vague Influential?

Irène Juhan‐vague's Published Works

Published Works

Irène Juhan‐vague's AcademicInfluence.com Rankings